Key statistics
On Friday, Tyra Biosciences Inc (TYRA:NSQ) closed at 16.11, 51.98% above the 52 week low of 10.60 set on Nov 29, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 16.69 |
---|---|
High | 16.96 |
Low | 15.84 |
Bid | 15.00 |
Offer | 17.29 |
Previous close | 17.15 |
Average volume | 690.10k |
---|---|
Shares outstanding | 52.81m |
Free float | 51.54m |
P/E (TTM) | -- |
Market cap | 850.71m USD |
EPS (TTM) | -1.69 USD |
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
- Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights
- Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)
- Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)
- Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET
- Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024)
- Tyra Biosciences to Present at the 2024 Cantor Global Healthcare Conference
- Tyra Biosciences Appoints Doug Warner, M.D., as Chief Medical Officer
More ▼